Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Peter Mollee, John Reynolds, Wojciech Janowski, Hang Quach, Philip Campbell, Simon D. Gibbs, Sophie Lee, James D'Rozario, Kerry Taylor, Tara Cochrane, Craig Thomas Wallington-Beddoe, Fiona Kwok, Nicholas Weber, Ian H Kerridge, Helen Weston, P. Joy Ho, Noemi Horvath, Flora Yuen, Andrew Spencer

Blood (2021) 138 (Supplement 1): 2728.

https://doi.org/10.1182/blood-2021-152500

Published: 2021

Journal Articles

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Peter Mollee, FRACP,MBBS,MSc,FRCPA, John Reynolds, PhD, Wojt Janowski, FRCPA,FRACP, Hang Quach, MDFRACP,FRCPA,MBBS, Philip Campbell, MBBS, Simon D. Gibbs, FRACP, FRCPA, MBBS, Sophie Lee, FRACP, FRCPA, PhD, James D'Rozario, MBBS, FRACP, FRCPA, Kerry Taylor, FRACP,FRCPA,MBBS, Tara Cochrane, MBBS,FRCPA,FRACP, Craig Thomas Wallington-Beddoe, BSc,MBBS,PhDFRACP,FRCPA, Fiona Kwok, FRACP,FRCPA,MBBS, Nicholas Weber, MBBS, Ian H. Kerridge, FRACP FRCPA MPhil BA, Helen Weston, MBBS, FRACP, FRCPA, Phoebe Joy Ho, MBBS,DPhil,FRACP,FRCPA, Noemi Horvath, MB ChB FRACP FRCPA, Flora Yuen, BBiomedSc, Andrew Spencer

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-138394

Published: 2020

Journal Articles

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-138953

Published: 2020

Journal Articles

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Georgia J McCaughan, MBBS, Steven Tran, BEng MBiomedE, Simon Durrant, MBBS FRCP FRCPath, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, James Morton, MBBS BSci (MD FRACP FRCPA GAICD, Noemi Horvath, MB ChB FRACP FRCPA, Andrew Spencer, Ian H. Kerridge, FRACP FRCPA MPhil BA, Jeremy An Ke Er, MBBS, Luani Barge, MChD, BSc, Adam Bryant, MBBS (Hon) PhDFRACP FRCPA, Robin J Filshie, MBChB, PhD FRACP, FRCPA, Emily Choong, BSc MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Campbell Tiley, MBBS FRACP, Anthony K Mills, MBBS FRACP FRCPA, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, John Moore, MB.BS, MD FRACP, FRCPA, Mark Hertzberg, MBBS PhDFRACP FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), M Hasib Sidiqi, MBBS, John Bashford, BSc MBBS FRACP FRCPA, David Routledge, BSc (Hons) MBChB MSc PGCert MRCP FRCPath UK RACP, Kerry Taylor, MBBS(Hons) FRACP FRCPA, Cindy H. Lee, MBBS FRACP FRCPA, Anna Kalff, MBBS (Hons) FRACP FRCPA, Wei Xia, MBBS PhD, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-138991

Published: 2020

Journal Articles

Pomalidomide Alone or in Combination with Low Dose Dexamethasone As Maintenance Following Induction with Pomalidomide and Low Dose Dexamethasone in Relapsed and Refractory Myeloma (ALLG MM14)

Anna Kalff, MBBS, Nola Kennedy, John Reynolds, PhD, Hang Quach, MDFRACP,FRCPA,MBBS, Phoebe Joy Ho, MBBS, Noemi Horvath, MBBS FRACP FRCPA, Peter Mollee, FRACP, FRCPA, MBBS, MMSc, James M. D'Rozario, MBBS, FRACP, FRCPA, Kerry Taylor, FRACP,FRCPA,MBBS, Jane Estell, FRACP, Andrew Spencer, MBBS, MD FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 1986.

https://doi.org/10.1182/blood-2018-99-118231

Published: 2018

Journal Articles

Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Blood (2018) 132 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2018-99-112847

Published: 2018

Journal Articles

Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)

Blood (2017) 130 (Supplement 1): 1509.

https://doi.org/10.1182/blood.V130.Suppl_1.1509.1509

Published: 2017

Journal Articles

Pathology Results of Tissue Biopsy during Idelalisib-Associated Diarrhea/Colitis

Cecilia C.S. Yeung, David M. Hockenbery, Maria Westerhoff, Steven Coutre, Ruth H. Sedlak, Ronald L. Dubowy, A. Mario Marcondes, Veerendra Munugalavadla, Kerry Taylor, Francesc Bosch

Blood (2016) 128 (22): 4391.

https://doi.org/10.1182/blood.V128.22.4391.4391

Published: 2016

Journal Articles

Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study

M Domenica Cappellini, MD, Amal El-Beshlawy, MD, John B Porter, MD, Antonis Kattamis, MD, PhD, Kerry Taylor, MD, Christian Rose, Vernon J Louw, MD, Ali El-Ali, MD, Nicolas Martin, MS, Norbert Gattermann, MD

Blood (2012) 120 (21): 5182.

https://doi.org/10.1182/blood.V120.21.5182.5182

Published: 2012

Journal Articles

All- trans -retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

Blood (2012) 120 (8): 1570–1580.

https://doi.org/10.1182/blood-2012-02-410746

Published: 2012

Journal Articles

Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria

Norbert Gattermann, MD, Carlo Finelli, MD, Matteo Della Porta, MD, Pierre Fenaux, MD, PhD, Michael Stadler, MD, Agnès Guerci-Bresler, MD, Mathias Schmid, MD, Kerry Taylor, MD, Dominique Vassilieff, MD, Dany Habr, MD, Andrea Marcellari, MS, MT(ASCP), Bernard Roubert, PhD, Christian Rose, MD

Blood (2010) 116 (21): 2912.

https://doi.org/10.1182/blood.V116.21.2912.2912

Published: 2010

Journal Articles

Correlation Between Decreased Serum Ferritin and Improved Liver Transaminases During Deferasirox (Exjade®) Treatment in Iron-Overloaded Patients with Myelodysplastic Syndromes.

Norbert Gattermann, Mathias Schmid, Agnès Guerci-Bresler, Matteo Della Porta, Kerry Taylor, Dany Habr, Gabor Domokos, Bernard Roubert, Pierre Fenaux

Blood (2009) 114 (22): 3803.

https://doi.org/10.1182/blood.V114.22.3803.3803

Published: 2009

Journal Articles

Deferasirox (Exjade®) Is Effective and Well Tolerated in Chelation-Naive and Previously Chelated Patients with Transfusion-Dependent Myelodysplastic Syndromes (MDS).

Mathias Schmid, Agnès Guerci-Bresler, Matteo Della Porta, Kerry Taylor, Dany Habr, Gabor Domokos, Bernard Roubert, Christian Rose, Norbert Gattermann, MD, PhD

Blood (2009) 114 (22): 3806.

https://doi.org/10.1182/blood.V114.22.3806.3806

Published: 2009

Journal Articles

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Blood (2009) 114 (22): 1125.

https://doi.org/10.1182/blood.V114.22.1125.1125

Published: 2009

Journal Articles

Efficacy and Safety of Deferasirox (Exjade ® ) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from EPIC Trial

Norbert Gattermann, Mathias Schmid, Matteo Della Porta, Kerry Taylor, John F Seymour, Dany Habr, Gabor Domokos, Abdel Hmissi, Agnès Guerci-Bresler, Christian Rose

Blood (2008) 112 (11): 633.

https://doi.org/10.1182/blood.V112.11.633.633

Published: 2008

Journal Articles

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Blood (2008) 112 (10): 3965–3973.

https://doi.org/10.1182/blood-2008-06-161737

Published: 2008

Includes: Supplemental data

Journal Articles

An Open-Label, Phase 2 Trial of Denosumab in the Treatment of Relapsed (R) or Plateau-Phase (PP) Multiple Myeloma (MM).

Ravi Vij, Noemi Horvath, Andrew Spencer, Kerry Taylor, Saroj Vadhan-Raj, Judy Smith, Yi Qian, Susie Jun

Blood (2007) 110 (11): 3604.

https://doi.org/10.1182/blood.V110.11.3604.3604

Published: 2007

Journal Articles

Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) Monitoring of Minimal Residual Disease (MRD) in Core Binding Factor Acute Myeloid Leukaemia (CBF AML).

Steven W. Lane, Russell Saal, Peter Mollee, Andrew Grigg, Kerry Taylor, John Francis Seymour, Glen Kennedy, Bronwyn Williams, Mark Jones, Karen Grimmett, Vanessa Griffiths, Devinder Gill, Matthew Hourigan, Paula Marlton

Blood (2006) 108 (11): 2296.

https://doi.org/10.1182/blood.V108.11.2296.2296

Published: 2006

Journal Articles

Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin alfa Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia.

Kerry Taylor, MD, Peter Ganly, MD, Veena Charu, MD, Joseph DiBenedetto, MD, Karolyn Kracht, PhD, Greg Rossi, PhD, Enrique Hernandez, MD

Blood (2005) 106 (11): 3556.

https://doi.org/10.1182/blood.V106.11.3556.3556

Published: 2005

Journal Articles

An Outpatient Salvage Approach for Advanced Lymphoma Incorporating Stratification and Dose-Escalation.

Andrew Spencer, DM, Andrew Grigg, MBBS, John Catalano, MBBS, Michael Leahy, MBBS, Craig Underhill, MBBS, Chris Arthur, MBBS, James DRozario, MBBS, Ray Lowenthal, DM, Kerry Taylor, MBBS

Blood (2005) 106 (11): 3336.

https://doi.org/10.1182/blood.V106.11.3336.3336

Published: 2005

NARROW

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Pomalidomide Alone or in Combination with Low Dose Dexamethasone As Maintenance Following Induction with Pomalidomide and Low Dose Dexamethasone in Relapsed and Refractory Myeloma (ALLG MM14)

Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)

Pathology Results of Tissue Biopsy during Idelalisib-Associated Diarrhea/Colitis

Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study

All- trans -retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria

Correlation Between Decreased Serum Ferritin and Improved Liver Transaminases During Deferasirox (Exjade®) Treatment in Iron-Overloaded Patients with Myelodysplastic Syndromes.

Deferasirox (Exjade®) Is Effective and Well Tolerated in Chelation-Naive and Previously Chelated Patients with Transfusion-Dependent Myelodysplastic Syndromes (MDS).

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Efficacy and Safety of Deferasirox (Exjade ® ) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from EPIC Trial

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

An Open-Label, Phase 2 Trial of Denosumab in the Treatment of Relapsed (R) or Plateau-Phase (PP) Multiple Myeloma (MM).

Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) Monitoring of Minimal Residual Disease (MRD) in Core Binding Factor Acute Myeloid Leukaemia (CBF AML).

Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin alfa Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia.

An Outpatient Salvage Approach for Advanced Lymphoma Incorporating Stratification and Dose-Escalation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only